期刊文献+

肥厚梗阻型心肌病化学消融术中、术后严重并发症及防治 被引量:5

Prevention and Treatment of Complications of Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy
下载PDF
导出
摘要 目的 :报告经皮室间隔心肌化学消融术治疗肥厚梗阻型心肌病术中、术后出现的严重并发症 ,探讨其原因和机制 ,总结经验、教训 ,以期减少其发生。方法 :2 0例肥厚梗阻型心肌病患者用Sigwart法行化学消融术 ,观察术中、术后出现的严重并发症。结果 :2 0例患者中合并下壁急性心肌梗死 2例 ,前壁心肌梗死 1例 ;术后心室颤动 1例 ;永久性Ⅲ度房室传导阻滞 1例 ;术后严重血流动力学障碍 1例 ;术中左冠状动脉回旋支栓塞 1例。结论 :肥厚梗阻型心肌病化学消融术中及术后可发生多种严重并发症 ,明确靶血管与消融心肌之间的关系、选择恰当的一支或多支间隔支动脉行化学消融 。 Objective: To reduce the serious complications of percutaneous transluminal septal myocardial ablation (PTSMA) in patients with hypertrophic obstructive cardiomyopathy (HOCM) Methods: Twenty patients with HOCM underwent PTSMA with Sigwart method The complications were observed during and after ablation Results: Out of the 20 patients inferior wall acute myocardial infarction was found in 2,anterior wall acute myocardial infarction in 1,ventricular fibrillation in 1,permanent complete atrio ventricular block in 1,severe hemodynamic obstruction in 1 and embolism in circumflex branch of left coronary artery in 1 Conclusion: Many complications may occur during and after PTSMA The key to reduce complications is to select one or multiple appropriate septal branch arteries for chemical ablation
出处 《中国循环杂志》 CSCD 北大核心 2002年第6期448-450,共3页 Chinese Circulation Journal
关键词 肥厚梗阻型心肌病 并发症 经皮室间隔心肌化学消融术 防治措施 介入治疗 Complication Cardiomyopathy,hypertrophic Percutaneous transluminal septal myocardial ablation
  • 相关文献

参考文献8

二级参考文献7

共引文献61

同被引文献40

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 2杨跃进主编.阜外心血管内科手册[M].北京:人民卫生出版社,2007.555-556.
  • 3Geisterfer-Lowrance aa, Kass S, Tanigawa, et al. Amoleeular basis for familial hypertrophic cardiomyopathy; a beta cardiac myosin heavy chain missense mutation[ J]. Cell, 1990,62(5) : 999 - 1006.
  • 4Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyophathy [J]. Lancet, 1995,346 (8969) : 211 - 214.
  • 5Mckenna WJ, carom AJ. Sudden death in hypertrophic cardlomyopathy: assessment of patients at high risk [ J ]. Circulation, 1989, 80 ( 5 ) : 1489 - 1492.
  • 6Seggewiss H, Faber L, Gleiehrmn U. Percutaneous transluminal septal mycardial in hypertropic obstructive cardiomyopathy [ J]. Thorac Cardiovase Surg, 1999,47(2) :94 - 100.
  • 7Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardlomyopathy[ J ]. Current Cardiol Rep, 2001,3 (2) : 160 - 166.
  • 8Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients [ J I. Circulation, 1997,95 (8) : 2075 - 2081.
  • 9Maron BJ, Nishimura RA, Mckenna WJ, et al. Assessment of permanent dualchamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypert ropic cardiomyopathy. A randomized double-blind, crossover study(M-PATHY ) [ J ]. Circulation, 1999,99(22 ) :2927 - 2933.
  • 10Eselka J, Prochazkova S, Duehonova R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamie and clinical out come [ J ]. Catheter Cardiovasc Interv,2004,63(2) :231 - 235.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部